Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Randomized, Single-dose, Open-label, Two-part, Two-period, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric With an Adult Formulation of Branaplam and to Investigate the Adult Formulation in Fed and Fasted State in Healthy Participants

ClinicalTrials.gov Identifier: NCT05330286

Novartis Reference Number: CLMI070A02104

Last Update: Jun 22, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This is a Phase 1 study designed to assess the relative bioavailability (BA), safety and tolerability and PK of the pediatric and adult formulations of branaplam.

Condition 
Healthy Volunteers
Phase 
Phase 1
Overall status 
Recruiting
Start date 
Apr 13, 2022
Completion date 
Aug 25, 2022
Gender 
All
Age(s)
18 Years - 60 Years (Adult)

Interventions

Drug
LMI070
oral solution
Drug
LMI070
Oral solution
Drug
LMI070
Oral solution given in fasted state
Drug
LMI070
Oral solution given in fed state

Eligibility Criteria

Inclusion Criteria:

Healthy male and non-childbearing potential female participants, 18 to 60 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening and baseline 1 (laboratory parameters are listed in Table 8-4.
Participants must weigh at least 50 kg at screening to participate in the study, and must have a body mass index within the range of 18.0 to 30.0 kg/m2 as measured at screening. Body mass index = Body weight (kg) / [Height (m)]2.

At screening and baseline vital signs (systolic blood pressure, diastolic blood pressure and pulse rate) will be assessed in the supine position and again in the standing position (after at least 3 minutes in each position). Oral body temperature will also be taken with the other supine vital sign assessments. Supine vital signs must be within the following ranges at screening and baseline 1:

oral body temperature 35.0-37.5 °C (inclusive)
systolic blood pressure, 90-139 mmHg (inclusive)
diastolic blood pressure, 50-89 mmHg (inclusive)
pulse rate, 40-90 bpm (inclusive) Participants should be excluded if their standing vital signs (relative to supine) show findings which, in the opinion of the Investigator, are associated with clinical manifestation of postural hypotension (i.e. absence of any other cause). An Investigator should carefully consider enrolling participants with either a > 20 mmHg decrease in systolic blood pressure or a > 10 mmHg decrease in diastolic blood pressure accompanied by a > 20 bpm increase in pulse rate.

Exclusion Criteria:

Participants who have received any investigational medicinal product in a clinical research study within the 90 days or 5 half-lives, whichever is longer, prior to Period 1 Day 1.
Participants who have previously been administered investigational medicinal product in this study. Participants who have taken part in Part 1 are not permitted to take part in Part 2.
Significant illness, which has not resolved within two (2) weeks prior to initial dosing.
Men planning to father children in the near future (next 6 months).
Male participant who reports to have a pregnant or nursing (lactating) partner.

Sexually active males unwilling to adhere to the contraception requirements of the study as detailed below:

A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner.
Males with partners of childbearing potential must use a condom during intercourse while taking investigational drug and for 118 days after stopping investigational drug (duration to cover one spermatogenesis cycle plus 5 half-lives).
Additionally, male participants with female partners of childbearing potential should also use another highly effective method of contraception. Highly effective contraception methods include:

Partner's bilateral tubal occlusion Male participant sterilization (vasectomy; at least 6 months prior to screening).

Partner's use of oral (estrogen and progesterone; or progesterone only that inhibits ovulation), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months.

Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
Males with partners of non-childbearing potential must use a condom during intercourse while taking investigational drug and for 28 days after stopping investigational drug (duration to cover 5 half lives).

In addition, male participants should not donate sperm for 118 days after stopping investigational drug.

Women of childbearing potential who report to be pregnant or nursing (lactating). Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. Women are considered not of child-bearing potential if they are post-menopausal or have had surgical bilateral salpingectomy or bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks before screening. Women are considered post menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) and serum follicle stimulating hormone concentration of ≥40 IU/L. Follicle stimulating hormone and luteinizing hormone testing is required of any female participant, regardless of reported reproductive/menopausal status at screening. Refer to Section 8.4.3 Pregnancy and Assessments of Fertility.

Study Locations

United Kingdom
Novartis Investigative Site
Recruiting
Mere Way, NG11 6JS
Nottingham
United Kingdom

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]